Articles tagged with: Carfilzomib
The year 2013 is likely to be remembered as a very good year when it comes to research related to multiple myeloma.
Previous years have witnessed research shedding new light on existing myeloma therapies, as well as additional research about potential new therapies.
But, in the past, most of the important new therapies that were being researched were from existing classes of therapy, making them less likely to offer dramatic improvements in the treatment of the disease.
In 2013, not only was there more research about existing therapies, and more …
The 2013 annual meeting of the American Society of Hematology (ASH), which took place last month, featured many oral and poster presentations about Kyprolis, one of the newest drugs to be approved for the treatment of multiple myeloma.
The drug continues to be tested in various combinations in both newly diagnosed and relapsed/refractory multiple myeloma patients, as well as in patients with the myeloma precursor disease smoldering myeloma.
Results from three clinical trials involving the investigational drug filanesib were presented at the American Society of Hematology (ASH) annual meeting earlier this month.
Overall, the trial results presented at ASH confirm existing impressions of filanesib as a promising potential myeloma therapy.
Results of a Phase 2 trial of filanesib with or without low-dose dexamethasone (Decadron) show that 16 percent of …
Monday was the third day of this year’s meeting of the American Society of Hematology (ASH). The day was filled with oral presentation sessions from early in the morning until into the evening.
In the afternoon and early evening, there were six oral presentation sessions devoted solely to multiple myeloma and a number of other myeloma-related presentations scattered about the afternoon. The topics of these presentations ranged from the biology of myeloma to treatment options for newly diagnosed, relapsed and refractory, and older patients.
This ASH update highlights most of …
Yesterday was the second day of the American Society of Hematology’s (ASH) annual meeting, which is being held in New Orleans.
As on Saturday, myeloma-related presentations were once again made during several sessions throughout the day.
Experts who missed the education session on Saturday had the opportunity to attend the session again early Sunday morning.
One myeloma study was presented during the plenary session in the early afternoon. The six presentations in this session covered all blood cancers and are considered particularly important studies.
The myeloma study included in this …